Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ONCODESIGN
  6. Summary
    ALONC   FR0011766229

ONCODESIGN

(ALONC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
9.88(c) 10.08(c) 10.14(c) 10(c) 9.96 Last
26 253 5 487 2 104 3 754 1 021 Volume
-2.56% +2.02% +0.60% -1.38% -0.40% Change
More quotes
Estimated financial data (e)
Sales 2021 32,0 M 36,3 M 36,3 M
Net income 2021 1,80 M 2,04 M 2,04 M
Net Debt 2021 1,73 M 1,96 M 1,96 M
P/E ratio 2021 -32,7x
Yield 2021 -
Sales 2022 52,3 M 59,3 M 59,3 M
Net income 2022 4,20 M 4,76 M 4,76 M
Net cash position 2022 7,81 M 8,85 M 8,85 M
P/E ratio 2022 6,52x
Yield 2022 -
Capitalization 68,3 M 77,5 M 77,4 M
EV / Sales 2021 2,19x
EV / Sales 2022 1,16x
Nbr of Employees 226
Free-Float 50,6%
More Financials
Company
Oncodesign SA is a France-based company that discovers and develops therapies against cancer. The Company's services include target identification, validation and cellular screens; preclinical research, in vivo screening and pharmacology; molecular pharmacology and biomarkers, pharmaco-imaging and immunology, among others. Its activities include preclinical evaluation services and discovery operations. The Company's... 
More about the company
Ratings of ONCODESIGN
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ONCODESIGN
2021Oncodesign Société Anonyme's Equity Buyback announced on February 15, 2021, has expired..
CI
2021Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bo..
CI
2021ONCODESIGN : Appoints Chief Development Officer
MT
2021Oncodesign Appoints Karine Lignel as Group Chief Development Officer
CI
2021ONCODESIGN : Nomination
CO
2021ONCODESIGN : Starts R&D Deal with TiumBio for Fibrosis Drug Candidates
MT
2021Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates
CI
2021Oncodesign Announces Unaudited Consolidated Sales Results for the Half Year Ended June ..
CI
2021ONCODESIGN : Half-year results
CO
2021GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
2021Oncodesign Announces Unaudited Consolidated Turnover Results for the First Half of 2021
CI
2021ONCODESIGN : 2nd quarter earnings
CO
2021Oncodesign Appoints Aline Aubertin as New Independent Director
CI
2021ONCODESIGN : Nomination
CO
2021Oncodesign Announces a Strategic Collaboration Agreement with Covalab
CI
More news
News in other languages on ONCODESIGN
2021Oncodesign nomme un directeur du développement
2021ONCODESIGN : le titre monte après un accord de collaboration
2021Oncodesign conclut un accord de R&D avec TiumBio pour des candidats médicaments contre ..
2021Pendant que PayPal épingle Pinterest, Evergrande fait son comeback
2021EN DIRECT DES MARCHES : Hermès, Carrefour, Atos, Eurofins, Soitec, Technip Energies, ABB, ..
More news
Chart ONCODESIGN
Duration : Period :
ONCODESIGN Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCODESIGN
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 10,00 €
Average target price 16,60 €
Spread / Average Target 66,0%
EPS Revisions
Managers and Directors
Philippe Genne Chairman & Chief Executive Officer
Arnaud Lafforgue Chief Financial & Administrative Officer
Jan Hoflack Chief Scientific Officer
Francis Bichat Director-Technology
Stéphane Gerart Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCODESIGN-0.79%77
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831